Fetal Growth Flashcards

1
Q

Fetal growth restriction definition (4)

A

a condition in which the fetus does not reach its
biological growth potential

  • Often equated to being small
  • Not all small fetuses are growth restricted
  • Not all growth restricted fetuses are small
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How do you define FGR? (3)

A
  • Growth involves increment in a time interval
  • Usual method is to plot fetal size against gestation
  • Various centile cut-offs are used for diagnosis of SGA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Causes of smallness (4)

A
  • Dating problems
  • Constitutional
  • Primary fetal/environmental
    problem
  • Placental insufficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Fetal/environment smallness factors (5)

A
  • Chromosomal conditions (e.g. Trisomy 18, Triploidy)
  • Congenital infections
    (e.g. Rubella, CMV)
  • Genetic syndromes
    (e.g. Russell-Silver syndrome)
  • Teratogens (e.g. Fetal alcohol syndrome, Drug abuse)
  • Maternal problem
    (e.g. Cyanotic CHD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Placental insufficiency (3)

A
  • Placenta function is nutrient and gas exchange
  • Poor function will lead to:
  • Slowing of growth
    *-Hypoxemia → Hypoxia → Asphyxia
  • Stillbirth
  • Ultrasound used to find evidence of
  • Placental dysfunction
  • Fetal response to the dysfunction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Placental insufficiency: Clinical setting

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Feto-maternal circulation

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Doppler flow basics

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

preg. doppler flow assessment

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

FGR changes in doppler flow

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Placenta mediated FGR definitions

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Detecting FGR (3)

A
  • Clinical: Symphysis-fundal height
  • Serial ultrasound biometry
  • Uterine artery Doppler screening
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Symphysis-fundal height (3)

A
  • One trial w/ 1639 women was available
  • Antenatal detection of small babies was
    lower in the fundal height group (28%)
    than abdominal palpation (48%)
  • No evidence of improved outcome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

routine 3rd trim US: (4)

A
  • Eight trials recruiting 27,024 women were included.
  • There was no difference in antenatal, obstetric and neonatal
    intervention or morbidity in screened versus control groups.
  • There was a slightly higher caesarean section rate in the screened
    group, but this difference did not reach statistical significance.
  • Routine late pregnancy ultrasound was not associated with
    improvements in overall perinatal mortality.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pregnancy Outcome Prediction Study (POPS)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Preterm FGR (<37 Wks) (2)

A
  • Diagnosis, fetal response and monitoring
    is well characterized
  • Pathophysiology and natural history is
    understood
17
Q

Preterm for Doppler changes

A
18
Q

Monitoring Umbilical artery (2)

A
  • Umbilical artery (UA) Doppler is of proven benefit

The authors conclude that the use of Doppler ultrasound on the umbilical artery in high-risk pregnancies reduces the risk of perinatal deaths and may result in fewer obstetric interventions.

19
Q

FGR: 28– 36wks (5)

A
  • Increased PI in UA is abnormal
  • Deliver for reversed EDF at 32 weeks
  • Deliver for absent EDF at 34 weeks
  • Deliver for PI > 95th at 37 weeks

NB. MCA Dopplers not needed (less than 37 weeks) if UA Dopplers are normal

20
Q

Truffle - when to deliver (<32wks) (6)

A
  • Early FGR <32 weeks = risk of IUD vs risk of prematurity
  • Ideal monitoring modality shown by the Trial of Umbilical
    and Fetal Flow in Europe (TRUFFLE) study
  • Included women with singleton at 26–32 weeks of gestation with FGR
  • 503 of 542 eligible women were randomly allocated to 3
    monitoring groups
  • 12 fetuses (2%) died in utero and 27 (6%) neonatal deaths
    occurred (92% survival)
  • More infants delivered due to late ductus changes were free of neuro-impairment
21
Q

Truffle: delivery criteria (3)

A

cCTG:
STV < 3.5msecs (<29w) or
STV <4msecs (>29w)
on two occasions on the
same day

Early DV:
Abnormal DV PI
(on two occasions on the
same day)

Late DV:
DV a-wave
Absent/reversed
(on two occasions on the
same day)

22
Q

COMPUTERISED CARDIOTOCOGRAPHY (cCTG)

A
23
Q

DUCTUS VENOSUS DOPPLER (3)

A

Normal:
Absent a wave:
Reversed a wave:

24
Q

FGR ≥ 37wks (6)

A
  • Increased PI in Umbilical artery is abnormal = DELIVER
  • Normal Umbilical artery PI alone is not enough
  • MCA Dopplers needed even if Umbilical artery Dopplers are normal
  • Deliver if MCA PI < 5th centile
  • At EFW <3rd centile, deliver at 37 weeks
  • At EFW 3rd – 10th centile, deliver at 39weeks
25
Q

Term GDR + neurodev. (4)

A
  • Several studies show a link b/w small fetuses and abnormal neurodevelopment
  • Etiology of subnormal development is
    unclear?- hypoxic injury
  • Among babies born at term, being SGA is associated with lower scores neurodevelopmental outcomes compared to
    AGA controls.
  • The standardized neurodevelopmental score in SGA babies was 0.32 SD (95% CI, 0.25–0.38) below those for normal controls.
26
Q

Impact of smallness (4)

A
  • Small fetuses often remain small later in life
  • Morbidity linked to smallness
  • Higher cerebral palsy rates
  • Genetic imprinting – genetic basis of adult disease
27
Q

Treatment Options controversy (2)

A
  • Sildenafil might improve fetal growth in utero by vasodilation.
  • Dutch STRIDER trial was stopped after 183 women were recruited; this decision was in response to concerns about a higher than expected neonatal mortality (19/71
    [27%] with sildenafil vs 9/63 [14%] with placebo) and high rates of
    persistent pulmonary hypertension of the neonate (PPHN) in the
    sildenafil group (17/64 [27%] sildenafil vs 3/58 [5%] placebo)
28
Q

Unanswered q’s (3)

A
  • Delivery timing for IUGR between 34 – 37 weeks: A trial is ongoing (TRUFFLE-2)
  • Monitoring for fetal well-being at term
  • What outcome variable is most important: survival, morbidity,
    neurodevelopmental score, adult health
29
Q

Summary (6)

A
  • Discuss the causes of a small fetus
  • Define the concept of fetal growth restriction (FGR)
  • Pathophysiology of poor placentation using Doppler assessment
  • Methods of detecting FGR
  • Diagnostic and management differences between preterm and term FGR
  • Describe adverse consequences of FGR